Active substance
Betamethasone
- SFDA 41
- US FDA 106
- Health Canada 21
- US price lines 19
- NHS prices 15
- WHO EML 1
- Safety 10
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| BETADERM 0.1% cream | 0.1 % | Cream · Topical | 1 Tube | SAR 4.20 | Generic · Prescription | EIPICO | Valid |
| BETADERM 0.1% ointment | 0.1 % | Ointment · Topical | 1 Tube | SAR 4.20 | Generic · Prescription | EIPICO | Valid |
| BETAMED 0.1% CREAM | 0.1 % | Cream · Topical | 1 Tube | SAR 2.95 | Generic · Prescription | MEDPHARMA PHARMACEUTICAL & CHEMICAL INDUSTRIES | Valid |
| BETAMED 0.1% TOPICAL OINTMENT | 0.1 % | Ointment · Topical | 1 Tube | SAR 2.95 | Generic · Prescription | MEDPHARMA PHARMACEUTICAL & CHEMICAL INDUSTRIES | Valid |
| BETASONE 0.1% CREAM | 0.1 % | Cream · Topical | 1 Tube | SAR 5.15 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| BETASONE 0.1% OINTMENT | 0.1 % | Ointment · Topical | 1 Tube | SAR 5.15 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| BETASONE 500MCG TAB | 0.5 mg | Tablet · Oral use | 20 Blister | SAR 6.70 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| BETNOVATE 0.1% SCALP APPLICATION | 0.1 % | Scalp solution · Topical | 1 Tube | SAR 13.65 | NCE · Prescription | GLAXO SAUDI ARABIA | Valid |
| BETNOVATE CREAM 0.1% | 0.1 % | Cream · Topical | 1 Tube | SAR 10.10 | Generic · Prescription | GLAXO SAUDI ARABIA | Valid |
| BETNOVATE OINTMENT 0.1% | 0.1 % | Ointment · Topical | 1 Tube | SAR 10.10 | Generic · Prescription | GLAXO SAUDI ARABIA | Valid |
| BEVASON 0.1% CREAM | 0.1 % | Cream · Topical | 1 Tube | SAR 4.00 | Generic · Prescription | OMAN PHARMACEUTICAL PRODUCTS | Valid |
| BEVASON 0.1% OINTMENT | 0.1 % | Ointment · Topical | 1 Tube | SAR 4.00 | Generic · Prescription | OMAN PHARMACEUTICAL PRODUCTS | Valid |
| DIPROFOS INJ. 2ML | 5,2 mg/ml,mg/ml | Suspension for injection · Intramuscular use | 1 Ampoule | SAR 25.40 | NCE · Prescription | Organon Belgium | Valid |
| DIPROLENE 0.05% OINT | 0.05 % | Ointment · Topical | 1 Tube | SAR 21.00 | Generic · Prescription | Organon Belgium | Valid |
| DIPROSONE CREAM 0.05% | 0.05 % | Cream · Topical | 1 Tube | SAR 17.85 | NCE · Prescription | Organon Belgium | Valid |
| DIPROSONE OINTMENT 0.05% | 0.05 % | Ointment · Topical | 1 Tube | SAR 17.85 | NCE · Prescription | Organon Belgium | Valid |
| TABETA 0.1%SCALP APPLICATION | 0.1 % | Cutaneous suspension · Topical | 1 Bottle | SAR 10.90 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| BETACORT 4MG-ML AMP | 4 mg/ml | Solution for injection · Intravenous use | 1 Ampoule | SAR 4.85 | Generic · Prescription | Hikma Pharmaceuticals PLC | Withdrawn by MAH · Not Marketed |
| BETAMET 0.1% OINTMENT | 0.1 % | Ointment · Topical | 1 Tube | SAR 5.15 | Generic · Prescription | SPIMACO ADDWAEIH | Withdrawn by MAH · Not Marketed |
| BETAVAL CREAM 0.1% | 0.1 % | Cream · Topical | 1 Tube | SAR 2.70 | Generic · Prescription | APM | Withdrawn by MAH · Not Marketed |
| BETAVAL OINT 0.1% | 0.1 % | Ointment · Topical | 1 Tube | SAR 2.70 | Generic · Prescription | APM | Withdrawn by MAH · Not Marketed |
| BETAVAL OINT 0.1% | 0.1 % | Ointment · Topical | 1 Tube | SAR 4.05 | Generic · Prescription | APM | Withdrawn by MAH · Not Marketed |
| BETONATE 0.1% CREAM | 0.1 % | Cream · Topical | 1 Tube | SAR 3.35 | Generic · Prescription | SHAPHACO PHARMACEUTICAL | Suspended · Not Marketed |
| BETONATE 0.1% OINTMENT | 0.1 % | Ointment · Topical | 1 Tube | SAR 3.35 | Generic · Prescription | SHAPHACO PHARMACEUTICAL | Suspended · Not Marketed |
| CELESTODERM-V CREAM 0.1% | 0.1 % | Cream · Topical | 1 Tube | SAR 9.80 | NCE · Prescription | SCHERING-PLOUGH | Withdrawn by MAH · Not Marketed |
16 more — full table
Indications — CHI Daman Drug Formulary
ANAL FISSURE; BEHCET DISEASE; ECZEMA; GRAFT VERSUS HOST DISEASE; HUMAN IMMUNODEFICIENCY VIRUS; LICHEN PLANUS; PEMPHIGUS; POLYCYTHEMIA VERA - PRURITUS; PSORIASIS; SYSTEMIC LUPUS ERYTHEMATOSUS; VITILIGO
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| CELESTONE SOLUSPAN | 3MG/ML;EQ 3MG BASE/ML | injectable · injection | ORGANON | Prescription | 3 Mar 1965 |
| BETA-VAL | EQ 0.1% BASE | cream · topical | COSETTE PHARMS NC | Prescription | 24 Mar 1983 |
| DIPROLENE | EQ 0.05% BASE | ointment, augmented · topical | ORGANON | Prescription | 27 Jul 1983 |
| BETAMETHASONE VALERATE | EQ 0.1% BASE | cream · topical | FOUGERA | Prescription | 31 Aug 1983 |
| BETAMETHASONE VALERATE | EQ 0.1% BASE | ointment · topical | FOUGERA | Prescription | 31 Aug 1983 |
| BETAMETHASONE VALERATE | EQ 0.1% BASE | lotion · topical | FOUGERA | Prescription | 31 Aug 1983 |
| BETAMETHASONE DIPROPIONATE | EQ 0.05% BASE | cream · topical | FOUGERA | Prescription | 26 Jun 1984 |
| BETAMETHASONE DIPROPIONATE | EQ 0.05% BASE | ointment · topical | FOUGERA | Prescription | 4 Sep 1984 |
| VALNAC | EQ 0.1% BASE | cream · topical | ACTAVIS MID ATLANTIC | Prescription | 10 Oct 1984 |
| BETAMETHASONE VALERATE | EQ 0.1% BASE | ointment · topical | ACTAVIS MID ATLANTIC | Prescription | 10 Oct 1984 |
| BETAMETHASONE VALERATE | EQ 0.1% BASE | lotion · topical | SENORES PHARMS | Prescription | 31 Jul 1985 |
| BETAMETHASONE DIPROPIONATE | EQ 0.05% BASE | lotion · topical | FOUGERA PHARMS INC | Prescription | 12 Aug 1985 |
| BETA-VAL | EQ 0.1% BASE | ointment · topical | COSETTE PHARMS NC | Prescription | 19 Dec 1985 |
| BETAMETHASONE DIPROPIONATE | EQ 0.05% BASE | cream · topical | ACTAVIS MID ATLANTIC | Prescription | 3 Feb 1987 |
| BETAMETHASONE DIPROPIONATE | EQ 0.05% BASE | ointment · topical | ACTAVIS MID ATLANTIC | Prescription | 3 Feb 1987 |
| BETAMETHASONE DIPROPIONATE | EQ 0.05% BASE | lotion · topical | COSETTE PHARMS NC | Prescription | 10 Aug 1987 |
| DERMABET | EQ 0.1% BASE | cream · topical | SUN PHARMA CANADA | Prescription | 6 Jan 1988 |
| BETAMETHASONE DIPROPIONATE | EQ 0.05% BASE | lotion · topical | PADAGIS US | Prescription | 31 Jan 1990 |
| BETAMETHASONE DIPROPIONATE | EQ 0.05% BASE | cream · topical | SUN PHARMA CANADA | Prescription | 30 Apr 1992 |
| BETAMETHASONE DIPROPIONATE | EQ 0.05% BASE | ointment, augmented · topical | ACTAVIS MID ATLANTIC | Prescription | 31 Aug 1995 |
| BETAMETHASONE DIPROPIONATE | EQ 0.05% BASE | ointment, augmented · topical | FOUGERA PHARMS | Prescription | 22 Jun 1999 |
| BETAMETHASONE DIPROPIONATE | EQ 0.05% BASE | gel, augmented · topical | FOUGERA PHARMS | Prescription | 13 May 2003 |
| BETAMETHASONE DIPROPIONATE | EQ 0.05% BASE | gel, augmented · topical | SUN PHARMA CANADA | Prescription | 2 Dec 2003 |
| BETAMETHASONE DIPROPIONATE | EQ 0.05% BASE | cream, augmented · topical | FOUGERA PHARMS | Prescription | 9 Dec 2003 |
| BETAMETHASONE DIPROPIONATE | EQ 0.05% BASE | cream, augmented · topical | SUN PHARMA CANADA | Prescription | 9 Dec 2003 |
81 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| BETADERM CRM 0.05% | 00716618 | 0.05 % | CREAM · TOPICAL | TARO PHARMACEUTICALS INC |
| BETADERM CRM 0.1% | 00716626 | 0.1 % | CREAM · TOPICAL | TARO PHARMACEUTICALS INC |
| BETADERM LOTION 0.1% | 00716634 | 0.1 % | LOTION · TOPICAL | TARO PHARMACEUTICALS INC |
| BETADERM ONT 0.05% | 00716642 | 0.05 % | OINTMENT · TOPICAL | TARO PHARMACEUTICALS INC |
| BETADERM ONT 0.1% | 00716650 | 0.1 % | OINTMENT · TOPICAL | TARO PHARMACEUTICALS INC |
| CELESTONE SOLUSPAN | 00028096 | 3 MG / ML; 3 MG / ML | SUSPENSION · INTRABURSAL; INTRA-ARTICULAR; INTRADERMAL; INTRAMUSCULAR | ORGANON CANADA INC. |
| DIPROLENE | 00629367 | 0.05 % / W/W | OINTMENT · TOPICAL | ORGANON CANADA INC. |
| DIPROSONE | 00323071 | 0.05 % / W/W | CREAM · TOPICAL | ORGANON CANADA INC. |
| DIPROSONE | 00344923 | 0.05 % / W/W | OINTMENT · TOPICAL | ORGANON CANADA INC. |
| DIPROSONE | 00417246 | 0.05 % / W/W | LOTION · TOPICAL | ORGANON CANADA INC. |
| TARO-SONE | 01925350 | 0.05 % | CREAM · TOPICAL | TARO PHARMACEUTICALS INC |
| TEVA-ECTOSONE | 00535427 | 0.05 % | CREAM · TOPICAL | TEVA CANADA LIMITED |
| TEVA-ECTOSONE | 00535435 | 0.1 % | CREAM · TOPICAL | TEVA CANADA LIMITED |
| TEVA-ECTOSONE | 00653209 | 0.05 % | LOTION · TOPICAL | TEVA CANADA LIMITED |
| TEVA-ECTOSONE | 00750050 | 0.1 % | LOTION · TOPICAL | TEVA CANADA LIMITED |
| TEVA-TOPILENE | 00849650 | 0.05 % | CREAM · TOPICAL | TEVA CANADA LIMITED |
| TEVA-TOPILENE | 00849669 | 0.05 % | OINTMENT · TOPICAL | TEVA CANADA LIMITED |
| TEVA-TOPILENE | 01927914 | 0.05 % | LOTION · TOPICAL | TEVA CANADA LIMITED |
| TEVA-TOPISONE | 00804991 | 0.05 % / W/W | CREAM · TOPICAL | TEVA CANADA LIMITED |
| TEVA-TOPISONE | 00805009 | 0.05 % / W/W | OINTMENT · TOPICAL | TEVA CANADA LIMITED |
| TEVA-TOPISONE | 00809187 | 0.05 % / W/W | LOTION · TOPICAL | TEVA CANADA LIMITED |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | BETAMETHASONE DP 0.05% CRM | $0.46459 | per GM | 23 Sep 2026 |
| US NADAC | BETAMETHASONE DP 0.05% CRM | $0.37111 | per GM | 23 Sep 2026 |
| US NADAC | BETAMETHASONE DP 0.05% LOT | $0.29237 | per ML | 23 Sep 2026 |
| US NADAC | BETAMETHASONE DP 0.05% OINT | $0.45991 | per GM | 23 Sep 2026 |
| US NADAC | BETAMETHASONE DP 0.05% OINT | $0.34942 | per GM | 23 Sep 2026 |
| US NADAC | BETAMETHASONE DP AUG 0.05% CRM | $0.12433 | per GM | 23 Sep 2026 |
| US NADAC | BETAMETHASONE DP AUG 0.05% CRM | $0.20938 | per GM | 23 Sep 2026 |
| US NADAC | BETAMETHASONE DP AUG 0.05% GEL | $2.73958 | per GM | 23 Sep 2026 |
| US NADAC | BETAMETHASONE DP AUG 0.05% GEL | $2.09456 | per GM | 22 Jul 2026 |
| US NADAC | BETAMETHASONE DP AUG 0.05% LOT | $0.49119 | per ML | 23 Sep 2026 |
| US NADAC | BETAMETHASONE DP AUG 0.05% LOT | $0.51026 | per ML | 23 Sep 2026 |
| US NADAC | BETAMETHASONE DP AUG 0.05% OIN | $0.58778 | per GM | 23 Sep 2026 |
| NHS Drug Tariff | Betamethasone 0.1% ear/eye/nose drops | £2.32 | 10 ml | 1 Oct 2026 |
| NHS Drug Tariff | Betamethasone 0.1% foam | £11.62 | 100 gram | 1 Oct 2026 |
| NHS Drug Tariff | Betamethasone 500microgram soluble tablets sugar free | £56.65 | 100 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Betamethasone dipropionate 0.05% cream | £6.12 | 100 gram | 1 Oct 2026 |
| NHS Drug Tariff | Betamethasone dipropionate 0.05% ointment | £2.16 | 30 gram | 1 Oct 2026 |
| NHS Drug Tariff | Betamethasone dipropionate 0.05% scalp lotion | £7.80 | 100 ml | 1 Oct 2026 |
| NHS Drug Tariff | Betamethasone valerate 0.025% cream | £3.15 | 100 gram | 1 Oct 2026 |
| NHS Drug Tariff | Betamethasone valerate 0.025% ointment | £3.15 | 100 gram | 1 Oct 2026 |
| NHS Drug Tariff | Betamethasone valerate 0.1% cream | £2.09 | 30 gram | 1 Oct 2026 |
| NHS Drug Tariff | Betamethasone valerate 0.1% cream | £5.63 | 100 gram | 1 Oct 2026 |
| NHS Drug Tariff | Betamethasone valerate 0.1% lotion | £4.58 | 100 ml | 1 Oct 2026 |
| NHS Drug Tariff | Betamethasone valerate 0.1% ointment | £1.51 | 30 gram | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 13.3. Dermatological medicines > Anti-inflammatory and antipruritic medicines · core
Dermatitis or eczema; Pruritus due to skin disorder; Psoriasis of unspecified type; Lichen planus
Local > Topical > Cream: 0.1% (as valerate) | Local > Topical > Ointment: 0.1% (as valerate)
Safety signals and safety-related labeling changes
- US FDA 8 Jul 2024 CELESTONE SOLUSPAN — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions - US FDA 8 Jul 2024 CELESTONE SOLUSPAN — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions - US FDA 16 Oct 2020 ENSTILAR — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 24 Mar 2020 SERNIVO — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 25 Jul 2019 TACLONEX — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 14 Jun 2019 LOTRISONE — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 1 May 2019 DIPROLENE — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 1 May 2019 DIPROLENE — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 1 May 2019 DIPROLENE AF — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 21 Dec 2018 TACLONEX — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Combinations containing Betamethasone
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.